Literature DB >> 2892544

Single-dose pharmacokinetics and bioavailability of famotidine in man. Results of multicenter collaborative studies.

K C Yeh1, A N Chremos, J H Lin, M L Constanzer, S M Kanovsky, H B Hucker, J Antonello, P Vlasses, J R Ryan, R L Williams.   

Abstract

Pharmacokinetics and bioavailability of famotidine, a new H2-receptor antagonist, were investigated in healthy subjects in five clinical studies. Linear pharmacokinetics were observed following either intravenous or oral administration. Plasma clearance averaged 463 ml min-1. Renal clearance averaged 310 ml min-1, which exceeded the glomerular filtration rate. Renal excretion was the major route of elimination. Urinary recovery of unchanged drug following intravenous administration was about 67 per cent. Famotidine plasma half-life was approximately 2.6 h. Oral absorption was incomplete. The bioavailability averaged 43 per cent of the dose.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2892544     DOI: 10.1002/bdd.2510080606

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  15 in total

Review 1.  Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations.

Authors:  J H Lin
Journal:  Clin Pharmacokinet       Date:  1991-03       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

3.  Pharmacokinetics of famotidine in elderly patients with and without renal insufficiency and in healthy young volunteers.

Authors:  N Inotsume; M Nishimura; S Fujiyama; K Sagara; T Sato; Y Imai; H Matsui; M Nakano
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 4.  Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  H D Langtry; S M Grant; K L Goa
Journal:  Drugs       Date:  1989-10       Impact factor: 9.546

5.  Famotidine. Pharmacokinetic properties and suppression of acid secretion in paediatric patients following cardiac surgery.

Authors:  G Kraus; D R Krishna; D Chmelarsch; M Schmid; U Klotz
Journal:  Clin Pharmacokinet       Date:  1990-01       Impact factor: 6.447

Review 6.  Newer H2-receptor antagonists. Clinical pharmacokinetics and drug interaction potential.

Authors:  D R Krishna; U Klotz
Journal:  Clin Pharmacokinet       Date:  1988-10       Impact factor: 6.447

7.  Pharmacokinetics of famotidine in infants.

Authors:  Larissa A Wenning; M Gail Murphy; Laura P James; Jeffrey L Blumer; James D Marshall; John Baier; Ann O Scheimann; Deborah L Panebianco; Ling Zhong; Roy Eisenhandler; Kuang C Yeh; Gregory L Kearns
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 8.  Pharmacokinetics and pharmacodynamics of famotidine in paediatric patients.

Authors:  L P James; G L Kearns
Journal:  Clin Pharmacokinet       Date:  1996-08       Impact factor: 6.447

9.  The Effect of Famotidine, a MATE1-Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin.

Authors:  Jennifer E Hibma; Arik A Zur; Richard A Castro; Matthias B Wittwer; Ron J Keizer; Sook Wah Yee; Srijib Goswami; Sophie L Stocker; Xuexiang Zhang; Yong Huang; Claire M Brett; Radojka M Savic; Kathleen M Giacomini
Journal:  Clin Pharmacokinet       Date:  2016-06       Impact factor: 6.447

Review 10.  Clinical pharmacokinetics of famotidine.

Authors:  H Echizen; T Ishizaki
Journal:  Clin Pharmacokinet       Date:  1991-09       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.